Success Metrics

Completion Rate
0%(0/3)
Active Trials
0(0%)
Terminated
3(100%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(3)

Detailed Status

Terminated3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

terminated3100%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_2

ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

NCT04639024
terminatedphase_1

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

NCT03621982
terminatedphase_1

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

NCT02588092

Clinical Trials (3)

Showing 3 of 3 trials
NCT04639024Phase 2

ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

Terminated
NCT03621982Phase 1

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Terminated
NCT02588092Phase 1

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3